Amedeo Smart

Free Medical Literature Service


 

Amedeo

Migraine

  Free Subscription

Articles published in
Headache
    March 2024
  1. KRIKOVA I, Digre KB, Katz BJ, Seay MD, et al
    Migraine, idiopathic intracranial hypertension, and calcitonin gene-related peptide antibodies.
    Headache. 2024 Mar 13. doi: 10.1111/head.14686.
    >> Share

  2. CHARLES AC, Digre KB, Goadsby PJ, Robbins MS, et al
    Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American Headache Society position statement update.
    Headache. 2024 Mar 11. doi: 10.1111/head.14692.
    >> Share

  3. SPROUSE BLUM AS, DaSilva LA, Greenberg MD, Nissenbaum AJ, et al
    Comparison of migraine with left- versus right-sided headache: A cross-sectional study.
    Headache. 2024 Mar 3. doi: 10.1111/head.14689.
    >> Share

  4. HOOGEVEEN ES, Pelzer N, Ghariq E, van Osch MJP, et al
    Cerebrovascular reactivity to hypercapnia in patients with migraine: A dual-echo arterial spin labeling MRI study.
    Headache. 2024 Mar 2. doi: 10.1111/head.14680.
    >> Share

  5. GIBLER RC, Knestrick KE, Powers SW, Hershey AD, et al
    Preliminary prospective observational investigation of clinical outcomes among treatment-seeking youth with continuous headache.
    Headache. 2024;64:319-322.
    >> Share

  6. LIPTON RB, Albrecht D, Bermudez M, Hu J, et al
    A randomized, open-label, 5-period crossover study evaluating the pharmacokinetics and safety of a single dose of intranasal dihydroergotamine (DHE) powder (STS101), intramuscular DHE mesylate, and liquid nasal spray DHE in healthy adults.
    Headache. 2024;64:266-275.
    >> Share

    February 2024
  7. SCUTELNIC A, Sutter NL, Beyeler M, Meinel TR, et al
    Characteristics of acute ischemic stroke and unusual aura in patients with migraine with aura.
    Headache. 2024 Feb 27. doi: 10.1111/head.14682.
    >> Share

  8. CHHABRA N, Mead-Harvey C, Dodoo CA, Iser C, et al
    Blood pressure elevation in erenumab-treated patients with migraine: A retrospective real-world experience.
    Headache. 2024 Feb 27. doi: 10.1111/head.14679.
    >> Share


  9. Correction to: "Once-daily oral atogepant for the long-term preventive treatment of migraine: Findings from a multicenter, randomized, open-label, phase 3 trial".
    Headache. 2024 Feb 26. doi: 10.1111/head.14691.
    >> Share

  10. ROSSIGNOL J, Ouimet T, Poras H, Dallel R, et al
    Synergistic effect of combining dual enkephalinase inhibitor PL37 and sumatriptan in a preclinical model of migraine.
    Headache. 2024 Feb 22. doi: 10.1111/head.14681.
    >> Share

  11. MITTLEMAN MR, Mostofsky E, Vgontzas A, Bertisch SM, et al
    Habitual caffeinated beverage consumption and headaches among adults with episodic migraine: A prospective cohort study.
    Headache. 2024 Feb 6. doi: 10.1111/head.14673.
    >> Share

  12. VAN DEN HOEK TC, Verhagen IE, de Boer I, Terwindt GM, et al
    Substance use in a Dutch migraine cohort compared with the general population.
    Headache. 2024 Feb 1. doi: 10.1111/head.14663.
    >> Share

  13. LANGDON RL, DiSabella MT, Strelzik JA
    Screen time and pediatric headache: A scoping review of the literature.
    Headache. 2024;64:211-225.
    >> Share

  14. HAN C, Lim JY, Koike N, Kim SY, et al
    Regulation of headache response and transcriptomic network by the trigeminal ganglion clock.
    Headache. 2024;64:195-210.
    >> Share

  15. JICHA C, Pham K
    Neuromodulation for primary headache disorders: Advantages and challenges.
    Headache. 2024;64:226-228.
    >> Share

  16. PRADHAN SK, Gantenbein AR, Li Y, Shaban H, et al
    Daith piercing: Revisited from the perspective of auricular acupuncture systems. A narrative review.
    Headache. 2024;64:131-140.
    >> Share

    January 2024
  17. ZHANG P, Ventrapragada A, Shapiro RE, Do TP, et al
    Metaphorical use of "headache" and "migraine" in media: A longitudinal study of 1.3 million articles in major publications.
    Headache. 2024 Jan 18. doi: 10.1111/head.14661.
    >> Share

  18. VGONTZAS A
    Examining substance use patterns in adults with migraine: A changing landscape.
    Headache. 2024 Jan 18. doi: 10.1111/head.14660.
    >> Share

  19. MANGRUM R, Bryant AL, Gerstein MT, McCarrier KP, et al
    The impacts of migraine on functioning: Results from two qualitative studies of people living with migraine.
    Headache. 2024 Jan 18. doi: 10.1111/head.14664.
    >> Share

  20. PATNIYOT I, Banerjee A, Nobleza K, Nguyen D, et al
    A retrospective analysis of the use of candesartan for migraine prevention in adolescents.
    Headache. 2024;64:96-97.
    >> Share

  21. DE OLIVEIRA FAA, Dourado-Filho MG, Sampaio Rocha-Filho PA
    Persistent headache attributed to past ischemic stroke: A prospective cohort study.
    Headache. 2024;64:48-54.
    >> Share

    December 2023
  22. BELTRAMONE M, Redon S, Donnet A
    Bone site fracture pain after subcutaneous sumatriptan injection: A report of two cases.
    Headache. 2023 Dec 29. doi: 10.1111/head.14662.
    >> Share

  23. RHUDY C, Schadler A, Huffmyer M, Porter L, et al
    Rural disparities in emergency department utilization for migraine care.
    Headache. 2023 Dec 12. doi: 10.1111/head.14659.
    >> Share

  24. CHASE BA, Semenov I, Rubin S, Meyers S, et al
    Characteristics associated with response to subcutaneously administered anti-CGRP monoclonal antibody medications in a real-world community cohort of persons living with migraine: A retrospective clinical and genetic study.
    Headache. 2023 Dec 10. doi: 10.1111/head.14655.
    >> Share

    November 2023
  25. PODRAZA K, Bangera N, Feliz A, Charles A, et al
    Reduction in retinal microvascular perfusion during migraine attacks.
    Headache. 2023 Nov 30. doi: 10.1111/head.14654.
    >> Share

  26. MACGREGOR EA, Okonkwo R, Detke HC, Polavieja P, et al
    Effect of galcanezumab in women with episodic migraine meeting criteria for menstrually related migraine: A post hoc analysis of EVOLVE-1 and EVOLVE-2.
    Headache. 2023 Nov 28. doi: 10.1111/head.14652.
    >> Share

  27. ASHINA M, Mitsikostas DD, Ramirez Campos V, Barash S, et al
    Numbers needed to treat or harm and likelihood of being helped versus harmed for fremanezumab in patients who had prior inadequate response to two to four classes of migraine preventive medications: A post hoc analysis.
    Headache. 2023 Nov 13. doi: 10.1111/head.14651.
    >> Share

  28. WU J, Yang P, Wu X, Yu X, et al
    Association between secondhand smoke exposure and severe headaches or migraine in never-smoking adults.
    Headache. 2023 Nov 8. doi: 10.1111/head.14640.
    >> Share

  29. SZPERKA CL, Witzman S, Ostapenko S, Farrar JT, et al
    Patient headache questionnaires can improve headache diagnosis and treatment in children.
    Headache. 2023;63:1359-1371.
    >> Share

  30. IACONANGELO CJ, Serrano D, Adams AM, Trugman JM, et al
    Evaluating therapeutic benefits of ubrogepant via latent class models: A post hoc exploratory analysis of the ACHIEVE I and ACHIEVE II trials.
    Headache. 2023;63:1412-1422.
    >> Share

  31. HYERACI G, Paoletti O, Iannone LF, Gini R, et al
    Patterns of anti-CGRP mAbs use and variation of triptan consumption following treatment initiation: A descriptive drug utilization study in the Tuscany region, Italy.
    Headache. 2023;63:1391-1402.
    >> Share

  32. MERLI E, Rustici A, Gramegna LL, Di Donato M, et al
    Vessel-wall MRI in primary headaches: The role of neurogenic inflammation.
    Headache. 2023;63:1372-1379.
    >> Share

    October 2023
  33. MOSKATEL LS, Graber-Naidich A, He Z, Zhang N, et al
    The introduction of the CGRP monoclonal antibodies and their effect on the prescription patterns of chronic migraine preventive medications in a tertiary headache center: A retrospective, observational analysis.
    Headache. 2023 Oct 26. doi: 10.1111/head.14642.
    >> Share

  34. CHIANG CC
    Hypermobility spectrum disorders and migraine in adolescents.
    Headache. 2023 Oct 24. doi: 10.1111/head.14650.
    >> Share

  35. PORTT AE, Orchard C, Chen H, Ge E, et al
    Migraine and air pollution: A systematic review.
    Headache. 2023 Oct 5. doi: 10.1111/head.14632.
    >> Share

  36. LIPTON RB, Pozo-Rosich P, Orr SL, Reed ML, et al
    Impact of monthly headache days on migraine-related quality of life: Results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) study.
    Headache. 2023 Oct 5. doi: 10.1111/head.14629.
    >> Share

  37. MCCRACKEN HT, Lee AA, Smitherman TA
    Headache and psychological variables as predictors of disability in individuals with primary headache disorders.
    Headache. 2023;63:1259-1270.
    >> Share

    September 2023
  38. MD ISA NA, Tummanapalli SS, Chiang JCB, Krishnan AV, et al
    Neuropathic changes in corneal nerve endings-A potential objective biomarker for migraine frequency and response to treatment.
    Headache. 2023 Sep 23. doi: 10.1111/head.14630.
    >> Share

  39. WANG VS, Kosman J, Yuan H, Lauritsen C, et al
    Safety, tolerability, and effectiveness of repetitive intravenous dihydroergotamine for refractory chronic migraine with cardiovascular risk factors: A retrospective study.
    Headache. 2023 Sep 23. doi: 10.1111/head.14636.
    >> Share

  40. KRUSE JA, Seng EK
    Changes in cognitive appraisal in a randomized controlled trial of mindfulness-based cognitive therapy for patients with migraine.
    Headache. 2023 Sep 18. doi: 10.1111/head.14627.
    >> Share

  41. SHAPIRO HFJ, Loder E, Shapiro DJ
    Association between clinician specialty and prescription of preventive medication for young adults with migraine: A retrospective cohort study.
    Headache. 2023 Sep 11. doi: 10.1111/head.14628.
    >> Share

  42. SILVA-NETO RP, Soares AA, Souza WPO, Krymchantowski AG, et al
    "Growing pains" in children and adolescents as an early symptom of migraine: A prospective study.
    Headache. 2023 Sep 6. doi: 10.1111/head.14608.
    >> Share

  43. CHARLES A
    Aura is a symptom of a migraine attack, not its cause.
    Headache. 2023 Sep 4. doi: 10.1111/head.14623.
    >> Share

  44. CLEMENTI MA, Kienzler C, Yonker M, Harmon M, et al
    Preliminary exploration of a multidimensional sleep health composite in adolescent females with frequent migraine.
    Headache. 2023 Sep 1. doi: 10.1111/head.14626.
    >> Share

  45. LIU H, Zhang S, Gong Z, Zhao W, et al
    Association between migraine and cardiovascular disease mortality: A prospective population-based cohort study.
    Headache. 2023 Sep 1. doi: 10.1111/head.14616.
    >> Share

  46. LEI X, Wei M, Wang L, Liu C, et al
    Resting-state electroencephalography microstate dynamics altered in patients with migraine with and without aura-A pilot study.
    Headache. 2023 Sep 1. doi: 10.1111/head.14622.
    >> Share

  47. TEPPER SJ, Schwedt TJ, Vo P, Thompson J, et al
    Healthcare costs and resource utilization in patients with migraine treated with erenumab: A retrospective, non-interventional study using claims data from the United States.
    Headache. 2023 Sep 1. doi: 10.1111/head.14612.
    >> Share

  48. MACGREGOR EA, Hutchinson S, Lai H, Dabruzzo B, et al
    Safety and efficacy of ubrogepant for the acute treatment of perimenstrual migraine attacks: A post hoc analysis.
    Headache. 2023 Sep 1. doi: 10.1111/head.14619.
    >> Share


  49. Correction to "Regional cerebral perfusion during the premonitory phase of triggered migraine: A double-blind randomized placebo-controlled functional imaging study using pseudo-continuous arterial spin labelling".
    Headache. 2023;63:1199.
    >> Share

  50. MARTINDALE C, Presson AP, Schwedt TJ, Brennan KC, et al
    Sensory hypersensitivities are associated with post-traumatic headache-related disability.
    Headache. 2023;63:1061-1069.
    >> Share

  51. FILA M, Pawlowska E, Szczepanska J, Blasiak J, et al
    Autophagy may protect the brain against prolonged consequences of headache attacks: A narrative/hypothesis review.
    Headache. 2023;63:1154-1166.
    >> Share

  52. KATSUKI M, Matsumori Y, Kawamura S, Kashiwagi K, et al
    Developing an artificial intelligence-based diagnostic model of headaches from a dataset of clinic patients' records.
    Headache. 2023;63:1097-1108.
    >> Share

    August 2023
  53. ZAMIR O, Yarns BC, Lagman-Bartolome AM, Jobanputra L, et al
    Understanding the gaps in headache and migraine treatment with psychological and behavioral interventions: A narrative review.
    Headache. 2023 Aug 28. doi: 10.1111/head.14624.
    >> Share

  54. POLK AN, Smitherman TA
    A meta-analytic review of acceptance-based interventions for migraine.
    Headache. 2023 Aug 27. doi: 10.1111/head.14614.
    >> Share

  55. RICHER L, Luu H, Martins KJB, Vu K, et al
    Trajectory of health care resources among adults stopping or reducing treatment frequency of botulinum toxin for chronic migraine treatment in Alberta, Canada.
    Headache. 2023 Aug 23. doi: 10.1111/head.14613.
    >> Share

  56. MATSUMORI Y, Ishida M, Iba K, Kim BK, et al
    Improved quality of life with fremanezumab in Japanese and Korean patients with episodic and chronic migraine: Results of two multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trials.
    Headache. 2023 Aug 21. doi: 10.1111/head.14606.
    >> Share

  57. KILINC YB, Kilinc E, Danis A, Hanci F, et al
    Mitochondrial metabolism related markers GDF-15, FGF-21, and HIF-1alpha are elevated in pediatric migraine attacks.
    Headache. 2023 Aug 19. doi: 10.1111/head.14618.
    >> Share

  58. ORNELLO R, Bruno F, Frattale I, Curcio G, et al
    White matter hyperintensities in migraine are not mediated by a dysfunction of the glymphatic system-A diffusion tensor imaging magnetic resonance imaging study.
    Headache. 2023 Aug 18. doi: 10.1111/head.14607.
    >> Share

  59. QIN Z, Qu H, Liang HB, Zhou Q, et al
    Altered resting-state effective connectivity of trigeminal vascular system in migraine without aura: A spectral dynamic causal modeling study.
    Headache. 2023 Aug 7. doi: 10.1111/head.14602.
    >> Share

  60. YANG L, Zhou Y, Zhang L, Wang Y, et al
    Aryl hydrocarbon receptors improve migraine-like pain behaviors in rats through the regulation of regulatory T cell/T-helper 17 cell-related homeostasis.
    Headache. 2023 Aug 4. doi: 10.1111/head.14599.
    >> Share

    July 2023
  61. NAHMAN-AVERBUCH H, Callahan D, Darken R, Haroutounian S, et al
    Harnessing the conditioned pain modulation response in migraine diagnosis, outcome prediction, and treatment-A narrative review.
    Headache. 2023 Jul 31. doi: 10.1111/head.14601.
    >> Share

  62. GELFAND AA, Allen IE, Grimes B, Irwin S, et al
    Melatonin for migraine prevention in children and adolescents: A randomized, double-blind, placebo-controlled trial after single-blind placebo lead-in.
    Headache. 2023 Jul 19. doi: 10.1111/head.14600.
    >> Share

  63. MEHNERT J, Fischer-Schulte L, May A
    Aura phenomena do not initiate migraine attacks-Findings from neuroimaging.
    Headache. 2023 Jul 14. doi: 10.1111/head.14597.
    >> Share

  64. DE VRIES LENTSCH S, Perenboom MJL, Carpay JA, MaassenVanDenBrink A, et al
    Visual hypersensitivity in patients treated with anti-calcitonin gene-related peptide (receptor) monoclonal antibodies.
    Headache. 2023;63:926-933.
    >> Share

  65. REIDY BL, Riddle EJ, Powers SW, Slater SK, et al
    Biopsychosocial treatment response among youth with continuous headache: A retrospective, clinic-based study.
    Headache. 2023;63:942-952.
    >> Share

    June 2023
  66. LANE IA, Zempsky WT
    Capturing the experiences of sexual and gender minorities with migraine headache.
    Headache. 2023 Jun 27. doi: 10.1111/head.14595.
    >> Share

  67. JICHA CJ, Alex A, Herskovitz S, Haut SR, et al
    Migraine with prolonged aphasic aura associated with a CACNA1A mutation: A case report and narrative review.
    Headache. 2023 Jun 27. doi: 10.1111/head.14594.
    >> Share

  68. NAGRI A, Patel M, Mwansisya T, Adebayo PB, et al
    Development and initial validation of the Kiswahili version of the Migraine Disability Assessment (MIDAS-K) questionnaire.
    Headache. 2023 Jun 27. doi: 10.1111/head.14592.
    >> Share

  69. DANNO D, Ishizaki K, Kikui S, Takeshima T, et al
    Treatment of hemiplegic migraine with anti-calcitonin gene-related peptide monoclonal antibodies: A case series in a tertiary-care headache center.
    Headache. 2023 Jun 27. doi: 10.1111/head.14591.
    >> Share

  70. BOCZARSKA-JEDYNAK M, Blumenfeld AM
    Injection technique of the upper face with onabotulinumtoxinA in chronic migraine.
    Headache. 2023 Jun 27. doi: 10.1111/head.14588.
    >> Share

  71. PERETZ A, Stark-Inbar A, Harris D, Tamir S, et al
    Safety of remote electrical neuromodulation for acute migraine treatment in pregnant women: A retrospective controlled survey-study.
    Headache. 2023 Jun 19. doi: 10.1111/head.14586.
    >> Share

  72. RODRIGUEZ-RIVAS R, Moreno-Martinez CA, Cerqueira TL, Enriquez-Peregrino KG, et al
    Translation, cross-cultural adaptation, and validation of a Latin American Spanish version of the ID Migraine screening test.
    Headache. 2023 Jun 16. doi: 10.1111/head.14509.
    >> Share

  73. MANGANO GD, Capizzi MR, Mantuano E, Veneziano L, et al
    Familial hemiplegic migraine in pediatric patients: A genetic, clinical, and follow-up study.
    Headache. 2023 Jun 16. doi: 10.1111/head.14582.
    >> Share

  74. COHEN F, Bobker S
    From diet to disasters, lifestyle factors can affect headaches and migraine.
    Headache. 2023 Jun 15. doi: 10.1111/head.14500.
    >> Share

  75. AHMED Z, Honomichl R, Thompson SF, Cohen JM, et al
    Clinical characteristics and patient-reported outcomes of chronic and episodic migraine patients at a US tertiary headache center: A retrospective observational study.
    Headache. 2023 Jun 14. doi: 10.1111/head.14527.
    >> Share

  76. YU B, Hou S, Xing Y, Jia Z, et al
    Ultrasound-guided stellate ganglion block for the treatment of migraine in elderly patients: A retrospective and observational study.
    Headache. 2023 Jun 14. doi: 10.1111/head.14537.
    >> Share

  77. TEPPER SJ, Lipton RB, Silberstein SD, Kudrow D, et al
    Long-term efficacy and safety of erenumab in patients with chronic migraine and acute medication overuse: A subgroup analysis.
    Headache. 2023 Jun 14. doi: 10.1111/head.14536.
    >> Share

  78. SENG EK, Parker A, Shapiro RE, Buse DC, et al
    Living in society, living with migraine: Editorial for the 2022 Members' Choice Award paper.
    Headache. 2023 Jun 14. doi: 10.1111/head.14530.
    >> Share

  79. ZLOOF Y, Simchoni M, Derazne E, Tsur AM, et al
    Hypermobility spectrum disorders and active migraine in Israeli adolescents: A nationwide study.
    Headache. 2023 Jun 14. doi: 10.1111/head.14526.
    >> Share

  80. ZHANG Y, Smith JH, Mullan AF, Vanmeter DE, et al
    Frequency of headache in emergency department patients with anaphylaxis: A cross-sectional study.
    Headache. 2023;63:834-838.
    >> Share

  81. KARSAN N, Bose RP, O'Daly O, Zelaya F, et al
    Regional cerebral perfusion during the premonitory phase of triggered migraine: A double-blind randomized placebo-controlled functional imaging study using pseudo-continuous arterial spin labeling.
    Headache. 2023;63:771-787.
    >> Share

  82. PARK SY, Kim J
    Characteristics of patients who visited emergency departments for headache in South Korea: A descriptive cross-sectional study.
    Headache. 2023;63:795-804.
    >> Share

    May 2023
  83. SACCA F, Braca S, Sansone M, Miele A, et al
    A head-to-head observational cohort study on the efficacy and safety of monoclonal antibodies against calcitonin gene-related peptide for chronic and episodic migraine.
    Headache. 2023 May 31. doi: 10.1111/head.14528.
    >> Share

  84. LAU CI, Chen WH, Wang HC, Walsh V, et al
    Decision-making impairment under ambiguity but not under risk may underlie medication overuse in patients with chronic migraine.
    Headache. 2023 May 26. doi: 10.1111/head.14513.
    >> Share

  85. HANS A, Stonnington CM, Zhang N, Butterfield R, et al
    The impact of resilience on headache disability as measured by the Migraine Disability Assessment (MIDAS).
    Headache. 2023 May 23. doi: 10.1111/head.14518.
    >> Share

  86. LIPTON RB, Sico J, Seng EK
    Migraine screening in English and Spanish.
    Headache. 2023 May 4. doi: 10.1111/head.14520.
    >> Share

  87. MANGRUM R, Gerstein MT, Hall CJ 3rd, Buse DC, et al
    Priority acute and preventive migraine treatment benefits: Results of the Migraine Clinical Outcome Assessment System (MiCOAS) qualitative study of people living with migraine.
    Headache. 2023 May 4. doi: 10.1111/head.14521.
    >> Share

  88. KELLIER DJ, de Prado BM, Haagen D, Grabner P, et al
    Validity of self-reported migraine in adolescents and children.
    Headache. 2023 May 4. doi: 10.1111/head.14498.
    >> Share

  89. TEPPER SJ, Dong Y, Vincent M, Wietecha LA, et al
    Sustained response of galcanezumab in migraine prevention: Patient-level data from a post hoc analysis in patients with episodic or chronic migraine.
    Headache. 2023 May 3. doi: 10.1111/head.14494.
    >> Share

  90. MEI HR, Hu YY, Kapadia S, Ouimet T, et al
    Efficacy of dual enkephalinase inhibition in a preclinical migraine model is mediated by activation of peripheral delta opioid receptors.
    Headache. 2023;63:621-633.
    >> Share

  91. ACKLEY E, Asamoah P, Mirsky D, White C, et al
    Dots and spots: A retrospective review of T2-hyperintense white matter lesions in pediatric patients with and without headache.
    Headache. 2023;63:611-620.
    >> Share

  92. HOULE TT, Smith MR, Turner DP
    Common challenges in the development of prediction models.
    Headache. 2023;63:569-570.
    >> Share

  93. KATSUKI M, Tatsumoto M, Kimoto K, Iiyama T, et al
    Investigating the effects of weather on headache occurrence using a smartphone application and artificial intelligence: A retrospective observational cross-sectional study.
    Headache. 2023;63:585-600.
    >> Share

    April 2023
  94. WANG Z, Lin Q, Peng YB
    Multi-region local field potential signatures and brain coherence alternations in response to nitroglycerin-induced migraine attacks.
    Headache. 2023 Apr 10. doi: 10.1111/head.14506.
    >> Share

  95. CHEN YJ, Hu KF, Chan C, Huang C, et al
    Association of periodontal disease with migraine: A large-scale community-based cross-sectional study.
    Headache. 2023 Apr 10. doi: 10.1111/head.14491.
    >> Share

  96. CARMILLO L, Fasano A
    Fremanezumab plus plasmapheresis in a patient with chronic migraine and myasthenia gravis: Case report of an effective treatment.
    Headache. 2023 Apr 10. doi: 10.1111/head.14497.
    >> Share

  97. THOMPSON AC, Goodbourn PT, Forte JD
    Perceived severity of Visual Snow Syndrome is associated with visual allodynia.
    Headache. 2023;63:494-505.
    >> Share

    March 2023
  98. OLIVEIRA FAA, Dourado-Filho MG, Sampaio Rocha-Filho PA
    Assessing the influence of migraine on ischemic penumbra and on the prognosis of ischemic stroke: A prospective cohort study.
    Headache. 2023 Mar 29. doi: 10.1111/head.14492.
    >> Share

  99. DIGRE KB
    Good New? Bad News? Idiopathic intracranial hypertension and migraine.
    Headache. 2023 Mar 29. doi: 10.1111/head.14489.
    >> Share

  100. GRAF M, Kim E, Brewer I, Hernandez J, et al
    Expert consensus established around flexible, individualized migraine treatment utilizing a modified Delphi panel.
    Headache. 2023 Mar 15. doi: 10.1111/head.14479.
    >> Share

  101. GERSTEIN MT, Wirth RJ, Uzumcu AA, Houts CR, et al
    Patient-reported experiences with migraine-related cognitive symptoms: Results of the MiCOAS qualitative study.
    Headache. 2023 Mar 10. doi: 10.1111/head.14484.
    >> Share

  102. VERHAGEN IE, van der Arend BWH, van Casteren DS, le Cessie S, et al
    Sex differences in migraine attack characteristics: A longitudinal E-diary study.
    Headache. 2023;63:333-341.
    >> Share

  103. KUDROW D, Dafer R, Dodick DW, Starling A, et al
    Evaluation of vascular risk in patients with migraine with and without aura treated with erenumab: Post hoc analysis of pooled long-term clinical trial data.
    Headache. 2023;63:418-428.
    >> Share

  104. BASEDAU H, Oppermann T, Gundelwein Silva E, Peng KP, et al
    Characterization of trigeminal C-fiber reactivity through capsaicin-induced release of calcitonin gene-related peptide.
    Headache. 2023;63:353-359.
    >> Share

  105. ACKLEY E, Gibler RC, Orr SL, Powers SW, et al
    Virtual issue: Recent advances in pediatric headache: Bridging the data gap.
    Headache. 2023;63:305-306.
    >> Share

    February 2023
  106. ESTAVE PM, Margol C, Beeghly S, Anderson R, et al
    Mechanisms of mindfulness in patients with migraine: Results of a qualitative study.
    Headache. 2023 Feb 28. doi: 10.1111/head.14481.
    >> Share

  107. LIPTON RB, Buse DC, Sandoe CH, Ford JH, et al
    Changes in migraine interictal burden following treatment with galcanezumab: Results from a phase III randomized, placebo-controlled study.
    Headache. 2023 Feb 16. doi: 10.1111/head.14460.
    >> Share

  108. GIBLER RC, Peugh JL, Coffey CS, Chamberlin LA, et al
    Impact of preventive pill-based treatment on migraine days: A secondary outcome study of the Childhood and Adolescent Migraine Prevention (CHAMP) trial and a comparison of self-report to nosology-derived assessments.
    Headache. 2023 Feb 9. doi: 10.1111/head.14474.
    >> Share

  109. BSTEH G, Macher S, Krajnc N, Pruckner P, et al
    Idiopathic intracranial hypertension presenting with migraine phenotype is associated with unfavorable headache outcomes.
    Headache. 2023 Feb 8. doi: 10.1111/head.14478.
    >> Share

  110. SCHWEDT TJ, Martin A, Kymes S, Talon B, et al
    Patient preferences for attributes of injected or infused preventive migraine medications: Findings from a discrete choice experiment.
    Headache. 2023 Feb 8. doi: 10.1111/head.14476.
    >> Share

  111. BUTLER N, Snyder IC, Korn TG, Nicholson RA, et al
    Lifetime history of an anxiety or depression disorder and adherence to medications used for the acute treatment of migraine.
    Headache. 2023 Feb 8. doi: 10.1111/head.14477.
    >> Share

  112. BATUR P, Yao M, Bucklan J, Soni P, et al
    Use of combined hormonal contraception and stroke: A case-control study of the impact of migraine type and estrogen dose on ischemic stroke risk.
    Headache. 2023 Feb 8. doi: 10.1111/head.14473.
    >> Share

  113. AL-KARAGHOLI MA, Kalatharan V, Ghanizada H, Dussor G, et al
    Prolactin in headache and migraine: A systematic review of preclinical studies.
    Headache. 2023 Feb 8. doi: 10.1111/head.14412.
    >> Share

  114. EZZATI A, Fanning KM, Reed ML, Lipton RB, et al
    Predictors of treatment-response to caffeine combination products, acetaminophen, acetylsalicylic acid (aspirin), and nonsteroidal anti-inflammatory drugs in acute treatment of episodic migraine.
    Headache. 2023 Feb 7. doi: 10.1111/head.14459.
    >> Share

  115. MOLLAN SP, Subramanian A, Perrins M, Nirantharakumar K, et al
    Depression and anxiety in women with idiopathic intracranial hypertension compared to migraine: A matched controlled cohort study.
    Headache. 2023 Feb 7. doi: 10.1111/head.14465.
    >> Share

  116. ZOLIN A, Broner SW, Yoo A, Guan I, et al
    Dystonia phenomenology and treatment response in migraine.
    Headache. 2023;63:255-263.
    >> Share

  117. MCGINLEY JS, Savord A, Buse DC, Wirth RJ, et al
    Longitudinal assessment of comorbidities and co-occurring conditions in adolescents with migraine: A secondary analysis of the National Longitudinal Study of Adolescent to Adult Health (Add Health).
    Headache. 2023;63:243-254.
    >> Share

  118. COCORES AN, Goadsby PJ, Monteith TS
    Post-vaccination headache reporting: Trends according to the Vaccine Adverse Events Reporting System.
    Headache. 2023;63:275-282.
    >> Share

  119. DODICK DW, Blumenfeld AM, Halker Singh RB, Williams R, et al
    Post hoc analysis of clinical trial data and pharmacokinetic data to assess wearing-off of erenumab within monthly treatment cycle.
    Headache. 2023;63:233-242.
    >> Share

    January 2023
  120. BASARI A, Boran HE, Vuralli D, Cengiz B, et al
    Visual temporal discrimination is impaired in patients with migraine without aura.
    Headache. 2023 Jan 27. doi: 10.1111/head.14466.
    >> Share

  121. WELANDER NZ, Rukh G, Rask-Andersen M, Harder AVE, et al
    Migraine, inflammatory bowel disease and celiac disease: A Mendelian randomization study.
    Headache. 2023 Jan 27. doi: 10.1111/head.14470.
    >> Share

  122. TEPPER SJ, Rabany L, Cowan RP, Smith TR, et al
    Remote electrical neuromodulation for migraine prevention: A double-blind, randomized, placebo-controlled clinical trial.
    Headache. 2023 Jan 27. doi: 10.1111/head.14469.
    >> Share

  123. VERHAAK A, Bakaysa S, Johnson A, Veronesi M, et al
    Migraine treatment in pregnancy: A survey of comfort and treatment practices of women's healthcare providers.
    Headache. 2023 Jan 25. doi: 10.1111/head.14436.
    >> Share

  124. ZHANG X, Wang W, Bai X, Zhang Y, et al
    Changes in gamma-aminobutyric acid and glutamate/glutamine levels in the right thalamus of patients with episodic and chronic migraine: A proton magnetic resonance spectroscopy study.
    Headache. 2023 Jan 18. doi: 10.1111/head.14449.
    >> Share

  125. ASHINA M, Tepper SJ, Reuter U, Blumenfeld AM, et al
    Once-daily oral atogepant for the long-term preventive treatment of migraine: Findings from a multicenter, randomized, open-label, phase 3 trial.
    Headache. 2023 Jan 18. doi: 10.1111/head.14439.
    >> Share

  126. CASANOVA A, Vives-Mestres M, Donoghue S, Mian A, et al
    The role of avoiding known triggers, embracing protectors, and adhering to healthy lifestyle recommendations in migraine prophylaxis: Insights from a prospective cohort of 1125 people with episodic migraine.
    Headache. 2023 Jan 18. doi: 10.1111/head.14451.
    >> Share

  127. STARLING AJ, Cowan RP, Buse DC, Diener HC, et al
    Eptinezumab improved patient-reported outcomes in patients with migraine and medication-overuse headache: Subgroup analysis of the randomized PROMISE-2 trial.
    Headache. 2023 Jan 12. doi: 10.1111/head.14434.
    >> Share

  128. BAHTIRI L, Thomsen AV, Ashina M, Hougaard A, et al
    Migraine aura-like episodes following sclerotherapy for varicose veins of the lower extremities-A systematic review.
    Headache. 2023 Jan 12. doi: 10.1111/head.14448.
    >> Share

  129. BLUMENFELD AM, Boinpally R, De Abreu Ferreira R, Trugman JM, et al
    Phase Ib, open-label, fixed-sequence, drug-drug interaction, safety, and tolerability study between atogepant and ubrogepant in participants with a history of migraine.
    Headache. 2023 Jan 5. doi: 10.1111/head.14433.
    >> Share

  130. URTECHO M, Wagner B, Wang Z, VanderPluym JH, et al
    A qualitative evidence synthesis of patient perspectives on migraine treatment features and outcomes.
    Headache. 2023 Jan 5. doi: 10.1111/head.14430.
    >> Share

  131. LIU H, Wang Q, Dong Z, Yu S, et al
    Dietary zinc intake and migraine in adults: a cross-sectional analysis of the National Health and Nutrition Examination Survey 1999-2004.
    Headache. 2023 Jan 1. doi: 10.1111/head.14431.
    >> Share

  132. STERN JI, Datta S, Chiang CC, Garza I, et al
    Narrative review of migraine management in patients with renal or hepatic disease.
    Headache. 2023;63:9-24.
    >> Share

  133. SCUTELNIC A, Slavova N, Klein A, Horvath T, et al
    Symptomatic visual snow in acute ischemic stroke: A case series.
    Headache. 2023;63:173-176.
    >> Share

  134. DONG Z, Liu K, Liu H, Jia Z, et al
    The prevalence and clinical features of fibromyalgia in Chinese hospital patients with primary headache: The survey of fibromyalgia comorbid with headache.
    Headache. 2023;63:62-70.
    >> Share

  135. ZORRILLA N, Gelfand AA, Irwin SL
    Eptinezumab for adolescents with chronic refractory headache: A retrospective chart review.
    Headache. 2023;63:177-182.
    >> Share

  136. BEGASSE DE DHAEM O, Wattiez AS, de Boer I, Pavitt S, et al
    Bridging the gap between preclinical scientists, clinical researchers, and clinicians: From animal research to clinical practice.
    Headache. 2023;63:25-39.
    >> Share

    November 2022
  137. KALTSEIS K, Hamann T, Gaul C, Broessner G, et al
    Is prednisone still a reasonable option in the treatment of withdrawal headache in patients with chronic migraine and medication overuse headache in the age of CGRP antibodies? A narrative review.
    Headache. 2022 Nov 27. doi: 10.1111/head.14415.
    >> Share

  138. VIVES-MESTRES M, Casanova A, Puig X, Ginebra J, et al
    Alcohol as a trigger of migraine attacks in people with migraine. Results from a large prospective cohort study in English-speaking countries.
    Headache. 2022 Nov 27. doi: 10.1111/head.14428.
    >> Share

  139. SOUZA MNP, Cohen JM, Piha T, Ribalov R, et al
    Burden of migraine in Brazil: A cross-sectional real-world study.
    Headache. 2022 Nov 25. doi: 10.1111/head.14413.
    >> Share

  140. THAXTER LY, Smitherman TA
    The effect of the COVID-19 pandemic on headache-related disability among young adults with migraine.
    Headache. 2022 Nov 23. doi: 10.1111/head.14411.
    >> Share

  141. GUI T, Li H, Zhu F, Wang Q, et al
    Different dosage regimens of erenumab for the treatment of migraine: A systematic review and meta-analysis of the efficacy and safety of randomized controlled trials.
    Headache. 2022 Nov 14. doi: 10.1111/head.14423.
    >> Share

  142. HENNINGSEN P, Hausteiner-Wiehle C, Hauser W
    Migraine in the context of chronic primary pain, chronic overlapping pain disorders, and functional somatic disorders: A narrative review.
    Headache. 2022 Nov 14. doi: 10.1111/head.14419.
    >> Share

  143. GARCIA-AZORIN D
    The complex relationship between alcohol and migraine.
    Headache. 2022 Nov 14. doi: 10.1111/head.14426.
    >> Share

  144. SENG EK, Shapiro RE, Buse DC, Robbins MS, et al
    The unique role of stigma in migraine-related disability and quality of life.
    Headache. 2022 Nov 2. doi: 10.1111/head.14401.
    >> Share

  145. BEDRIN K, Ailani J, Dougherty C
    Raynaud's phenomenon associated with calcitonin gene-related peptide receptor antagonists case report.
    Headache. 2022;62:1419-1423.
    >> Share

  146. DHOOT R, Sengupta S
    Recurrent painful ophthalmoplegic neuropathy with headache and oculomotor palsy 18 years apart.
    Headache. 2022;62:1434-1436.
    >> Share

  147. CARLSEN LN, Bendtsen L, Jensen RH, Schytz HW, et al
    Telephone follow-up on treatment and patient satisfaction at a Danish tertiary headache center: A prospective study.
    Headache. 2022;62:1312-1321.
    >> Share

  148. MEMBRILLA JA, Torres-Ferrus M, Alpuente A, Caronna E, et al
    Efficacy and safety of galcanezumab as a treatment of refractory episodic and chronic cluster headache: Case series and narrative review.
    Headache. 2022;62:1395-1405.
    >> Share

    October 2022
  149. CROOP R, Madonia J, Stock DA, Thiry A, et al
    Zavegepant nasal spray for the acute treatment of migraine: A Phase 2/3 double-blind, randomized, placebo-controlled, dose-ranging trial.
    Headache. 2022 Oct 14. doi: 10.1111/head.14389.
    >> Share

  150. GARELJA ML, Hay DL
    A narrative review of the calcitonin peptide family and associated receptors as migraine targets: Calcitonin gene-related peptide and beyond.
    Headache. 2022 Oct 13. doi: 10.1111/head.14388.
    >> Share

  151. FOFI L, Altamura C, Fiorentini G, Brunelli N, et al
    Improving distress perception and mutuality in migraine caregivers after 6 months of galcanezumab treatment.
    Headache. 2022 Oct 7. doi: 10.1111/head.14400.
    >> Share

  152. HARPE J, Bernstein C, Harriott A
    Migraine and infertility, merging concepts in women's reproductive health: A narrative review.
    Headache. 2022 Oct 6. doi: 10.1111/head.14402.
    >> Share

  153. YONKER ME, McVige J, Zeitlin L, Visser H, et al
    A multicenter, randomized, double-blind, placebo-controlled, crossover trial to evaluate the efficacy and safety of zolmitriptan nasal spray for the acute treatment of migraine in patients aged 6 to 11 years, with an open-label extension.
    Headache. 2022;62:1207-1217.
    >> Share

  154. STERN JI, Chiang CC, Kissoon NR, Robertson CE, et al
    Narrative review of peripheral nerve blocks for the management of headache.
    Headache. 2022;62:1077-1092.
    >> Share

  155. FISCHER-SCHULTE L, May A
    The 15-day threshold in the definition of chronic migraine is reasonable and sufficient-Five reasons for not changing the ICHD-3 definition.
    Headache. 2022;62:1231-1233.
    >> Share

  156. BELTRAMONE M, Redon S, Fernandes S, Ducros A, et al
    The teaching of headache medicine in France: A questionnaire-based study.
    Headache. 2022;62:1177-1186.
    >> Share

  157. ORR SL, Shapiro RE
    The elephant in the room: How the underfunding of headache research stunts the field.
    Headache. 2022;62:1234-1238.
    >> Share

    September 2022
  158. BURCH R
    A non-oral gepant for acute treatment of migraine.
    Headache. 2022 Sep 16. doi: 10.1111/head.14397.
    >> Share

  159. KUDROW D, Nguyen L, Semler J, Stroud C, et al
    A phase IV clinical trial of gastrointestinal motility in adult patients with migraine before and after initiation of a calcitonin gene-related peptide ligand (galcanezumab) or receptor (erenumab) antagonist.
    Headache. 2022 Sep 16. doi: 10.1111/head.14390.
    >> Share

  160. LI D, Guo Y, Xia M, Zhang J, et al
    Dietary intake of thiamine and riboflavin in relation to severe headache or migraine: A cross-sectional survey.
    Headache. 2022 Sep 1. doi: 10.1111/head.14384.
    >> Share

  161. HUBIG LT, Smith T, Chua GN, Lloyd AJ, et al
    A stated preference survey to explore patient preferences for novel preventive migraine treatments.
    Headache. 2022 Sep 1. doi: 10.1111/head.14386.
    >> Share

    August 2022
  162. LOPEZ-BRAVO A, Oliveros-Cid A, Minguez-Olaondo A, Cuadrado ML, et al
    Nummular headache responsive to anti-calcitonin gene-related peptide monoclonal antibodies in a patient with migraine.
    Headache. 2022 Aug 26. doi: 10.1111/head.14372.
    >> Share

  163. OLIVEIRA AB, Peres MFP, Mercante JPP, Molina MDCB, et al
    Physical activity pattern and migraine according to aura symptoms in the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil) cohort: A cross-sectional study.
    Headache. 2022 Aug 26. doi: 10.1111/head.14380.
    >> Share

  164. MONTERREY P, Gonzalez M, Ramirez D, Gracia F, et al
    Characteristics of migraine in patients with headache disorders: A clinic-based study from Central American and Caribbean countries.
    Headache. 2022 Aug 26. doi: 10.1111/head.14375.
    >> Share

    July 2022
  165. NAGARAJ K, Wei DY, Puledda F, Weng HY, et al
    Comparison and predictors of chronic migraine vs. new daily persistent headache presenting with a chronic migraine phenotype.
    Headache. 2022 Jul 21. doi: 10.1111/head.14362.
    >> Share

  166. CHIANG CC, Schwedt TJ, Dodick DW
    Exploring the association between migraine and atrial fibrillation utilizing a novel artificial intelligence-ECG algorithm.
    Headache. 2022 Jul 21. doi: 10.1111/head.14366.
    >> Share

  167. MUELLER BR, Robinson-Papp J
    Postural orthostatic tachycardia syndrome and migraine: A narrative review.
    Headache. 2022 Jul 19. doi: 10.1111/head.14365.
    >> Share

  168. LEE W, Cho SJ, Hwang H, Lee M, et al
    Crystal-clear days and unclear days in migraine: A population-based study.
    Headache. 2022 Jul 14. doi: 10.1111/head.14359.
    >> Share

  169. BEMANALIZADEH M, Baghaei Oskouei H, Hadizadeh A, Dakkali MS, et al
    Paroxysmal hemicrania in children and adolescents: A systematic review.
    Headache. 2022 Jul 14. doi: 10.1111/head.14354.
    >> Share

  170. MARTAMI F, Jayedi A, Shab-Bidar S
    Primary headache disorders and body mass index categories: A systematic review and dose-response meta-analysis.
    Headache. 2022;62:801-810.
    >> Share

  171. MOSKATEL LS, Smirnoff L
    Protracted headache after COVID-19: A case series of 31 patients from a tertiary headache center.
    Headache. 2022;62:903-907.
    >> Share

  172. RADZIWON J, Waszak P
    Seasonal changes of internet searching suggest circannual rhythmicity of primary headache disorders.
    Headache. 2022;62:811-817.
    >> Share

    June 2022
  173. TEPPER SJ, Grosberg B, Daniel O, Kuruvilla DE, et al
    Migraine treatment with external concurrent occipital and trigeminal neurostimulation-A randomized controlled trial.
    Headache. 2022 Jun 24. doi: 10.1111/head.14350.
    >> Share

  174. BERTELS Z, Mangutov E, Conway C, Siegersma K, et al
    Migraine and peripheral pain models show differential alterations in neuronal complexity.
    Headache. 2022 Jun 8. doi: 10.1111/head.14352.
    >> Share

  175. CHIANG CC, Chhabra N, Chao CJ, Wang H, et al
    Migraine with aura associates with a higher artificial intelligence: ECG atrial fibrillation prediction model output compared to migraine without aura in both women and men.
    Headache. 2022 Jun 8. doi: 10.1111/head.14339.
    >> Share

  176. PERO A, Pace A, Dhamoon MS
    Triptan medication use among patients with migraine with contraindications in the US.
    Headache. 2022 Jun 7. doi: 10.1111/head.14327.
    >> Share

  177. CASANOVA A, Vives-Mestres M, Donoghue S, Mian A, et al
    An observational study of self-reported migraine triggers and prospective evaluation of the relationships with occurrence of attacks enabled by a smartphone application (App).
    Headache. 2022 Jun 7. doi: 10.1111/head.14328.
    >> Share

  178. RICHER LP, Ali S, Johnson DW, Rosychuk RJ, et al
    A randomized trial of ketorolac and metoclopramide for migraine in the emergency department.
    Headache. 2022 Jun 7. doi: 10.1111/head.14307.
    >> Share

  179. BUOITE STELLA A, Filingeri D, Garascia G, D'Acunto L, et al
    Skin wetness sensitivity across body sites commonly affected by pain in people with migraine.
    Headache. 2022 Jun 7. doi: 10.1111/head.14323.
    >> Share

  180. GELFAND AA, Halker Singh RB, Robbins MS
    Worsening migraine: Another casualty of natural disasters.
    Headache. 2022 Jun 7. doi: 10.1111/head.14325.
    >> Share

  181. COWAN RP, Rapoport AM, Blythe J, Rothrock J, et al
    Diagnostic accuracy of an artificial intelligence online engine in migraine: A multi-center study.
    Headache. 2022 Jun 3. doi: 10.1111/head.14324.
    >> Share

  182. SAMPAIO ROCHA-FILHO PA
    Headache associated with COVID-19: Epidemiology, characteristics, pathophysiology, and management.
    Headache. 2022;62:650-656.
    >> Share

    May 2022
  183. EZZATI A, Fanning KM, Buse DC, Pavlovic JM, et al
    Predictive models for determining treatment response to nonprescription acute medications in migraine: Results from the American Migraine Prevalence and Prevention Study.
    Headache. 2022 May 11. doi: 10.1111/head.14312.
    >> Share

  184. LEE DA, Lee HJ, Park KM
    Normal glymphatic system function in patients with migraine: A pilot study.
    Headache. 2022 May 11. doi: 10.1111/head.14320.
    >> Share

  185. SCHWEDT TJ, Robert T, Dodick DW
    Treatment of chronic migraine with medication overuse: A perspective.
    Headache. 2022 May 6. doi: 10.1111/head.14314.
    >> Share

  186. HSU TW, Chen MH, Chu CS, Tsai SJ, et al
    Attention deficit hyperactivity disorder and risk of migraine: A nationwide longitudinal study.
    Headache. 2022 May 6. doi: 10.1111/head.14306.
    >> Share

  187. KHAYATA MJ, Farley S, Davis JK, Hornik CP, et al
    Beyond pain control: Outcome and treatment preferences in pediatric migraine.
    Headache. 2022 May 6. doi: 10.1111/head.14315.
    >> Share

  188. SCHIM JD, Anderson C, Brunner E, Hirman J, et al
    Likelihood of response with subsequent dosing for patients with migraine and initial suboptimal response with eptinezumab: A post hoc analysis of two placebo-controlled randomized clinical trials.
    Headache. 2022 May 6. doi: 10.1111/head.14302.
    >> Share

  189. CARVALHO GF, Luedtke K, Pinheiro CF, Moraes R, et al
    Migraine and balance impairment: Influence of subdiagnosis, otoneurological function, falls, and psychosocial factors.
    Headache. 2022;62:548-557.
    >> Share

  190. ASHINA M, Tepper SJ, Brandes JL, Reuter U, et al
    Long-term efficacy and safety of erenumab in patients with chronic migraine in whom prior preventive treatments had failed: A subgroup analysis.
    Headache. 2022;62:624-633.
    >> Share

  191. LEIBOVIT-REIBEN Z, Ishii R, Dodick DW, Dumkrieger G, et al
    The impact of pre-morbid headaches on headache features and long-term health outcomes following traumatic brain injury: Insights from the American Registry for Migraine Research.
    Headache. 2022;62:566-576.
    >> Share

  192. ZEBENHOLZER K, Gall W, Gleiss A, Pavelic AR, et al
    Triptans and vascular comorbidity in persons over fifty: Findings from a nationwide insurance database - A cohort study.
    Headache. 2022;62:604-612.
    >> Share

  193. YOUSEF YENGEJ D, Nwaobi SE, Ferando I, Kechechyan G, et al
    Different characteristics of cortical spreading depression in the sleep and wake states.
    Headache. 2022;62:577-587.
    >> Share

    April 2022
  194. NAHMAN-AVERBUCH H, Schneider VJ 2nd, Lee GR, Peugh JL, et al
    New insight into the neural mechanisms of migraine in adolescents: Relationships with sleep.
    Headache. 2022 Apr 25. doi: 10.1111/head.14299.
    >> Share

  195. TU YH, Wang YF, Yuan H, Chen SP, et al
    Most bothersome symptoms in patients with migraine: A hospital-based study in Taiwan.
    Headache. 2022 Apr 25. doi: 10.1111/head.14308.
    >> Share

  196. VIG SJ, Garza J, Tao Y
    The use of erenumab for migraine prophylaxis during pregnancy: A case report and narrative review.
    Headache. 2022 Apr 25. doi: 10.1111/head.14305.
    >> Share

  197. OKAZAKI Y, Yoshida S, Kashima S, Koike S, et al
    Impact of the 2018 Japan Floods on prescriptions for migraine: A longitudinal analysis using the National Database of Health Insurance Claims.
    Headache. 2022 Apr 25. doi: 10.1111/head.14301.
    >> Share

  198. LIPTON RB, Goadsby PJ, Dodick DW, McGinley JS, et al
    Evaluating the clinical utility of the patient-identified most bothersome symptom measure from PROMISE-2 for research in migraine prevention.
    Headache. 2022 Apr 25. doi: 10.1111/head.14295.
    >> Share

  199. BECKER WJ, Spacey S, Leroux E, Giammarco R, et al
    A real-world, observational study of erenumab for migraine prevention in Canadian patients.
    Headache. 2022 Apr 10. doi: 10.1111/head.14291.
    >> Share

  200. FERRARI MD, Zuurbier KWM, Barash S, Ning X, et al
    Fremanezumab in individuals with chronic migraine who had inadequate response to onabotulinumtoxinA and topiramate or valproic acid.
    Headache. 2022 Apr 6. doi: 10.1111/head.14294.
    >> Share

  201. SILVESTRO M, Tessitore A, Orologio I, Battista G, et al
    Cluster headache pathophysiology: What we have learned from advanced neuroimaging.
    Headache. 2022;62:436-452.
    >> Share

    March 2022
  202. HARRIS L, L'Italien G, Kumar A, Seelam P, et al
    Real-world assessment of the relationship between migraine-related disability and healthcare costs in the United States.
    Headache. 2022 Mar 28. doi: 10.1111/head.14289.
    >> Share

  203. SENG EK, Lipton RB
    Do behavioral treatments work for migraine prevention?
    Headache. 2022 Mar 16. doi: 10.1111/head.14290.
    >> Share

  204. BUSE DC, Gerstein MT, Houts CR, McGinley JS, et al
    Impact of the COVID-19 pandemic on people living with migraine: Results of the MiCOAS qualitative study.
    Headache. 2022 Mar 16. doi: 10.1111/head.14274.
    >> Share

  205. CARVALHO GF, Becnel AR, Miske C, Szikszay TM, et al
    Postural control impairment in patients with headaches-A systematic review and meta-analysis.
    Headache. 2022;62:241-270.
    >> Share

    February 2022
  206. AILANI J, Winner P, Hartry A, Brevig T, et al
    Patient preference for early onset of efficacy of preventive migraine treatments.
    Headache. 2022 Feb 20. doi: 10.1111/head.14255.
    >> Share

  207. GRECO R, Demartini C, Zanaboni AM, Francavilla M, et al
    The endocannabinoid system and related lipids as potential targets for the treatment of migraine-related pain.
    Headache. 2022 Feb 18. doi: 10.1111/head.14267.
    >> Share

  208. KLAN T, Brascher AK, Klein S, Diezemann-Prossdorf A, et al
    Assessing attack-related fear in headache disorders-Structure and psychometric properties of the Fear of Attacks in Migraine Inventory.
    Headache. 2022 Feb 18. doi: 10.1111/head.14272.
    >> Share

  209. TIETJEN GE
    The relationship of childhood adversity and migraine and the value of prospective studies.
    Headache. 2022 Feb 9. doi: 10.1111/head.14268.
    >> Share

  210. TEPPER SJ, Sheikh HU, Dougherty CO, Nahas SJ, et al
    Erenumab dosage for migraine prevention: An evidence-based narrative review with recommendations.
    Headache. 2022 Feb 9. doi: 10.1111/head.14266.
    >> Share

  211. KAWATA AK, Ladd MK, Lipton RB, Buse DC, et al
    Reducing the physical, social, and emotional impact of episodic migraine: Results from erenumab STRIVE and ARISE phase III randomized trials.
    Headache. 2022 Feb 8. doi: 10.1111/head.14258.
    >> Share

  212. DUDENEY J, Sharpe L, McDonald S, Menzies RE, et al
    Are psychological interventions efficacious for adults with migraine? A systematic review and meta-analysis.
    Headache. 2022 Feb 5. doi: 10.1111/head.14260.
    >> Share

  213. DI ANTONIO S, Castaldo M, Ponzano M, Bovis F, et al
    Trigeminal and cervical sensitization during the four phases of the migraine cycle in patients with episodic migraine.
    Headache. 2022 Feb 5. doi: 10.1111/head.14261.
    >> Share

  214. GOLLION C, Guidolin B, Lerebours F, Rousseau V, et al
    Migraine and large artery atherosclerosis in young adults with ischemic stroke.
    Headache. 2022 Feb 5. doi: 10.1111/head.14265.
    >> Share

  215. HAMMOND NG, Colman I, Orr SL
    Adverse childhood experiences and onset of migraine in Canadian adolescents: A cohort study.
    Headache. 2022 Feb 5. doi: 10.1111/head.14256.
    >> Share

  216. GIL YE, Lee MJ, Cho S, Chung CS, et al
    Effect of caffeine and caffeine cessation on cerebrovascular reactivity in patients with migraine.
    Headache. 2022 Feb 3. doi: 10.1111/head.14263.
    >> Share

  217. SHAO Q, Rascati KL, Barner JC, Lawson KA, et al
    Healthcare utilization and costs among patients with chronic migraine, episodic migraine, and tension-type headache enrolled in commercial insurance plans.
    Headache. 2022;62:141-158.
    >> Share

  218. AILANI J, Kuruppu DK, Rettiganti M, Oakes T, et al
    Does "wearing off" of efficacy occur in galcanezumab-treated patients at the end of the monthly treatment cycle? Post hoc analyses of four phase III randomized trials.
    Headache. 2022;62:198-207.
    >> Share

    January 2022
  219. LIPTON RB, Nicholson RA, Reed ML, Araujo AB, et al
    Diagnosis, consultation, treatment, and impact of migraine in the US: Results of the OVERCOME (US) study.
    Headache. 2022 Jan 25. doi: 10.1111/head.14259.
    >> Share

  220. ARTEMENKO AR, Filatova E, Vorobyeva YD, Do TP, et al
    Migraine and light: A narrative review.
    Headache. 2022;62:4-10.
    >> Share

  221. ELSER H, Skajaa N, Ehrenstein V, Fuglsang CH, et al
    Cancer risk in patients with migraine: A population-based cohort study in Denmark.
    Headache. 2022;62:57-64.
    >> Share

    December 2021
  222. MASON BN, Kallianpur R, Price TJ, Akopian AN, et al
    Prolactin signaling modulates stress-induced behavioral responses in a preclinical mouse model of migraine.
    Headache. 2021 Dec 29. doi: 10.1111/head.14248.
    >> Share

  223. LIPTON RB, Gandhi P, Stokes J, Cala ML, et al
    Development and validation of a novel patient-reported outcome measure in people with episodic migraine and chronic migraine: The Activity Impairment in Migraine Diary.
    Headache. 2021 Dec 28. doi: 10.1111/head.14229.
    >> Share

  224. AILANI J, Blumenfeld AM
    Combination CGRP monoclonal antibody and onabotulinumtoxinA treatment for preventive treatment in chronic migraine.
    Headache. 2021 Dec 7. doi: 10.1111/head.14244.
    >> Share

  225. BURCH RC, Ailani J, Robbins MS
    The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice.
    Headache. 2021 Dec 7. doi: 10.1111/head.14245.
    >> Share

  226. OLIVEIRA ADP, Silva-Neto RP
    Circadian rhythmicity on red ear syndrome in a patient with migraine: A case report.
    Headache. 2021 Dec 7. doi: 10.1111/head.14242.
    >> Share

  227. GONZALEZ-MARTINEZ A, Trillo Senin S, Benavides Bernaldo de Queiros C, Casado Fernandez L, et al
    Clinical characteristics and perfusion-computed tomography alterations in a series of patients with migraine with aura attended as stroke code.
    Headache. 2021 Dec 3. doi: 10.1111/head.14243.
    >> Share

    November 2021
  228. CHARLES JA, Turner IM
    AHS 2021 consensus on integrating new migraine therapies into clinical practice: Isn't our goal choice of best therapy regardless of cost?
    Headache. 2021 Nov 28. doi: 10.1111/head.14232.
    >> Share

  229. MCALLISTER PJ, Turner I, Reuter U, Wang A, et al
    Timing and durability of response to erenumab in patients with episodic migraine.
    Headache. 2021 Nov 28. doi: 10.1111/head.14233.
    >> Share

  230. LEE JH, Shewale AR, Barthold D, Devine B, et al
    Geographic variation in the use of triptans and opioids for the acute treatment of migraine attacks.
    Headache. 2021 Nov 28. doi: 10.1111/head.14238.
    >> Share

  231. OZKAN E, Gursoy-Ozdemir Y
    Occipital bending in migraine with visual aura.
    Headache. 2021 Nov 28. doi: 10.1111/head.14240.
    >> Share

  232. GLADSTONE J, Chhibber S, Minhas J, Neish CS, et al
    Real-world persistence of erenumab for preventive treatment of chronic and episodic migraine: Retrospective real-world study.
    Headache. 2021 Nov 22. doi: 10.1111/head.14218.
    >> Share

  233. KAZI F, Manyapu M, Fakherddine M, Mekuria K, et al
    Second-line interventions for migraine in the emergency department: A narrative review.
    Headache. 2021 Nov 22. doi: 10.1111/head.14239.
    >> Share

  234. CHARLES A, Nwaobi SE, Goadsby P
    Inflammation in migraine...or not...: A critical evaluation of the evidence.
    Headache. 2021 Nov 22. doi: 10.1111/head.14224.
    >> Share

  235. VYAS MV, Saposnik G, Lay C
    Migraine and sun avoidance behaviors in Canadian adults.
    Headache. 2021 Nov 2. doi: 10.1111/head.14227.
    >> Share

  236. RAGAB AH, Kishk NA, Hassan A, Yacoub O, et al
    Changes in migraine characteristics over 30 days of Ramadan fasting: A prospective study.
    Headache. 2021 Nov 2. doi: 10.1111/head.14231.
    >> Share

  237. HINDIYEH N
    Can we anticipate how Ramadan fasting will affect migraine?
    Headache. 2021;61:1463-1464.
    >> Share

  238. KELLY AM, Kuan WS, Chu KH, Kinnear FB, et al
    Epidemiology, investigation, management, and outcome of headache in emergency departments (HEAD study)-A multinational observational study.
    Headache. 2021;61:1539-1552.
    >> Share

    October 2021
  239. YUAN H, Curran JG, Keith SW, Hopkins MM, et al
    Intravenous ibuprofen for acute treatment of migraine: A double-blind, randomized, placebo-controlled pilot study.
    Headache. 2021 Oct 3. doi: 10.1111/head.14214.
    >> Share

  240. GALLARDO VJ, Alpuente A, Cerda-Company X, Torres-Ferrus M, et al
    The impact of a digital platform on migraine patient-centered outcome research. Evaluation of midolordecabeza.org, a headache website in Spanish.
    Headache. 2021 Oct 3. doi: 10.1111/head.14225.
    >> Share

  241. PRICE A, Sumner P, Powell G
    Subjective sensory sensitivity and its relationship with anxiety in people with probable migraine.
    Headache. 2021;61:1342-1350.
    >> Share

  242. NABITY PS, Jaramillo CA, Resick PA, McGeary CA, et al
    Persistent posttraumatic headaches and functioning in veterans: Injury type can matter.
    Headache. 2021;61:1334-1341.
    >> Share

  243. STRAUSS LD, Yugrakh MS, Kaplan KE, Minen MT, et al
    Headache infusion centers: A survey on treatments provided, infusion center operations, and barriers to developing new infusion centers.
    Headache. 2021;61:1364-1375.
    >> Share

    September 2021
  244. DODICK DW, Tepper SJ, Ailani J, Pannacciulli N, et al
    Risk of hypertension in erenumab-treated patients with migraine: Analyses of clinical trial and postmarketing data.
    Headache. 2021 Sep 30. doi: 10.1111/head.14208.
    >> Share

  245. KLEIN A, Schankin CJ
    Visual snow syndrome, the spectrum of perceptual disorders, and migraine as a common risk factor: A narrative review.
    Headache. 2021 Sep 27. doi: 10.1111/head.14213.
    >> Share

  246. MARMURA MJ, Diener HC, Cowan RP, Tepper SJ, et al
    Preventive migraine treatment with eptinezumab reduced acute headache medication and headache frequency to below diagnostic thresholds in patients with chronic migraine and medication-overuse headache.
    Headache. 2021 Sep 22. doi: 10.1111/head.14206.
    >> Share

  247. CHARLES A
    Memantine for migraine-Big promise but little evidence.
    Headache. 2021;61:1151-1152.
    >> Share

  248. SENG EK
    Stress and migraine: I know it when I see it.
    Headache. 2021;61:1153-1155.
    >> Share

  249. YALINAY DIKMEN P, Ertas M, Kosak S, Cimentepe C, et al
    Primary headaches among gender dysphoric female-to-male individuals: A cross-sectional survey on gender transition experience.
    Headache. 2021;61:1194-1206.
    >> Share

  250. HOULE TT, Deng H, Tegeler CH, Turner DP, et al
    Continuous updating of individual headache forecasting models using Bayesian methods.
    Headache. 2021;61:1264-1273.
    >> Share

  251. BREEN ID, Mangold AR, VanderPluym JH
    The evolving understanding of risk with calcitonin gene-related peptide monoclonal antibodies based on real-world data: A focus on hypertension and Raynaud phenomenon.
    Headache. 2021;61:1274-1276.
    >> Share

  252. FREITAG FG
    Everything old is new again.
    Headache. 2021;61:1286.
    >> Share

    August 2021
  253. KIM SK, Nikolova S, Schwedt TJ
    Structural aberrations of the brain associated with migraine: A narrative review.
    Headache. 2021 Aug 18. doi: 10.1111/head.14189.
    >> Share

  254. SPIERINGS ELH, Ning X, Ramirez Campos V, Cohen JM, et al
    Improvements in quality of life and work productivity with up to 6 months of fremanezumab treatment in patients with episodic and chronic migraine and documented inadequate response to 2 to 4 classes of migraine-preventive medications in the phase 3b
    Headache. 2021 Aug 10. doi: 10.1111/head.14196.
    >> Share

  255. VIVES-MESTRES M, Casanova A, Hershey AD, Orr SL, et al
    Perceived stress and pain severity in individuals with chronic migraine: A longitudinal cohort study using daily prospective diary data.
    Headache. 2021 Aug 9. doi: 10.1111/head.14199.
    >> Share

  256. ZHANG N, Woldeamanuel YW
    Medication overuse headache in patients with chronic migraine using cannabis: A case-referent study.
    Headache. 2021 Aug 9. doi: 10.1111/head.14195.
    >> Share

  257. TEPPER SJ, Lucas S, Ashina M, Schwedt TJ, et al
    Timing and durability of response to erenumab in patients with chronic migraine.
    Headache. 2021 Aug 7. doi: 10.1111/head.14193.
    >> Share

  258. SMITH TR, Winner P, Aurora SK, Jeleva M, et al
    STOP 301: A Phase 3, open-label study of safety, tolerability, and exploratory efficacy of INP104, Precision Olfactory Delivery (POD((R)) ) of dihydroergotamine mesylate, over 24/52 weeks in acute treatment of migraine attacks in adult patients.
    Headache. 2021 Aug 7. doi: 10.1111/head.14184.
    >> Share

  259. CARONNA E, Alpuente A, Torres-Ferrus M, Pozo-Rosich P, et al
    Toward a better understanding of persistent headache after mild COVID-19: Three migraine-like yet distinct scenarios.
    Headache. 2021 Aug 7. doi: 10.1111/head.14197.
    >> Share

  260. COHEN F, Friedman BW
    A randomized study of IV prochlorperazine plus diphenhydramine versus IV hydromorphone for migraine-associated symptoms: A post hoc analysis.
    Headache. 2021 Aug 7. doi: 10.1111/head.14185.
    >> Share

  261. MISTRY VM, Morizio PL, Pepin MJ, Bryan WE, et al
    Role of memantine in the prophylactic treatment of episodic migraine: A systematic review.
    Headache. 2021 Aug 5. doi: 10.1111/head.14186.
    >> Share

    July 2021
  262. SAKAI F, Suzuki N, Kim BK, Igarashi H, et al
    Efficacy and safety of fremanezumab for chronic migraine prevention: Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients.
    Headache. 2021 Jul 29. doi: 10.1111/head.14169.
    >> Share

  263. SAKAI F, Suzuki N, Kim BK, Tatsuoka Y, et al
    Efficacy and safety of fremanezumab for episodic migraine prevention: Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients.
    Headache. 2021 Jul 29. doi: 10.1111/head.14178.
    >> Share

  264. BARBANTI P, Aurilia C, Cevoli S, Egeo G, et al
    Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study.
    Headache. 2021 Jul 26. doi: 10.1111/head.14194.
    >> Share

  265. ARCA KN, VanderPluym JH, Halker Singh RB
    Narrative review of neuroimaging in migraine with aura.
    Headache. 2021 Jul 26. doi: 10.1111/head.14191.
    >> Share

  266. THOMSEN AV, Sorensen MT, Ashina M, Hougaard A, et al
    Symptomatic migraine: A systematic review to establish a clinically important diagnostic entity.
    Headache. 2021 Jul 12. doi: 10.1111/head.14187.
    >> Share

  267. SAMPAIO ROCHA-FILHO PA, Albanes Oliveira Bernardo A
    The usefulness of osmophobia for the diagnosis of migraine in children and adolescents.
    Headache. 2021 Jul 4. doi: 10.1111/head.14175.
    >> Share

  268. ISHII R
    Should chronic migraine be defined by eight or more headache days per month?
    Headache. 2021;61:983-984.
    >> Share

  269. WELLS RE, Estave PM, Burch R, Haas N, et al
    The value of the patient perspective in understanding the full burden of migraine.
    Headache. 2021;61:985-987.
    >> Share

  270. MINEN MT, Szperka CL, Kaplan K, Ehrlich A, et al
    Telehealth as a new care delivery model: The headache provider experience.
    Headache. 2021;61:1123-1131.
    >> Share

  271. KUMAR G, Payne AM, Maag LM, MacDonald S, et al
    Efficacy of a pediatric headache infusion center: A single-center experience.
    Headache. 2021;61:1086-1091.
    >> Share

  272. CARLSEN LN, Rouw C, Westergaard ML, Nielsen M, et al
    Treatment of medication overuse headache: Effect and predictors after 1 year-A randomized controlled trial.
    Headache. 2021;61:1112-1122.
    >> Share

    June 2021
  273. AILANI J, Burch RC, Robbins MS
    The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice.
    Headache. 2021 Jun 23. doi: 10.1111/head.14153.
    >> Share

  274. TAKESHIMA T, Sakai F, Hirata K, Imai N, et al
    Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study.
    Headache. 2021 Jun 21. doi: 10.1111/head.14138.
    >> Share

  275. RIZZOLI PB, Grazzi L
    Adaptation of the management of chronic migraine patients with medication overuse to the suspension of treatment protocols during the COVID-19 pandemic: Lessons from a tertiary headache center in Milan-6-month results.
    Headache. 2021 Jun 21. doi: 10.1111/head.14140.
    >> Share

  276. BHARADWAJ VN, Porreca F, Cowan RP, Kori S, et al
    A new hypothesis linking oxytocin to menstrual migraine.
    Headache. 2021 Jun 14. doi: 10.1111/head.14152.
    >> Share

  277. BARBANTI P, Fofi L, Grazzi L, Vernieri F, et al
    Clinical features, disease progression, and use of healthcare resources in a large sample of 866 patients from 24 headache centers: A real-life perspective from the Italian chROnic migraiNe (IRON) project.
    Headache. 2021 Jun 14. doi: 10.1111/head.14123.
    >> Share

  278. GRAZZI L, Andrasik F, Rizzoli P, Bernstein C, et al
    Acceptance and commitment therapy for high frequency episodic migraine without aura: Findings from a randomized pilot investigation.
    Headache. 2021 Jun 11. doi: 10.1111/head.14139.
    >> Share

  279. ASHINA M, Cohen JM, Gandhi SK, Du E, et al
    Reduction in the severity and duration of headache following fremanezumab treatment in patients with episodic and chronic migraine.
    Headache. 2021 Jun 11. doi: 10.1111/head.14127.
    >> Share

  280. SILVA-NETO RP
    Could osmophobia be a clinical diagnostic marker for migraine?
    Headache. 2021 Jun 9. doi: 10.1111/head.14148.
    >> Share

  281. KIM BK, Cho S, Kim HY, Chu MK, et al
    Validity and reliability of the self-administered Visual Aura Rating Scale questionnaire for migraine with aura diagnosis: A prospective clinic-based study.
    Headache. 2021 Jun 9. doi: 10.1111/head.14133.
    >> Share

  282. ISHII R, Schwedt TJ, Dumkrieger G, Lalvani N, et al
    Chronic versus episodic migraine: The 15-day threshold does not adequately reflect substantial differences in disability across the full spectrum of headache frequency.
    Headache. 2021 Jun 3. doi: 10.1111/head.14154.
    >> Share

  283. ESTAVE PM, Beeghly S, Anderson R, Margol C, et al
    Learning the full impact of migraine through patient voices: A qualitative study.
    Headache. 2021 Jun 3. doi: 10.1111/head.14151.
    >> Share

  284. SCHUSTER NM, Gasperi M
    Not just preaching to the CHOIR-A map for improving comprehensive care of patients with chronic migraine and comorbid non-cephalic pain.
    Headache. 2021;61:805-807.
    >> Share

  285. JOSHI S, Tepper SJ, Lucas S, Rasmussen S, et al
    A narrative review of the importance of pharmacokinetics and drug-drug interactions of preventive therapies in migraine management.
    Headache. 2021;61:838-853.
    >> Share

  286. LIANG Z, Thomas L, Jull G, Minto J, et al
    Neck pain associated with migraine does not necessarily reflect cervical musculoskeletal dysfunction.
    Headache. 2021;61:882-894.
    >> Share

  287. NAHMAN-AVERBUCH H, Hershey AD, Peugh JL, King CD, et al
    The promise of mechanistic approaches to understanding how youth with migraine get better-An Editorial to the 2020 Members' Choice Award Paper.
    Headache. 2021;61:803-804.
    >> Share

  288. BARAD MJ, Sturgeon JA, Hong J, Aggarwal AK, et al
    Characterization of chronic overlapping pain conditions in patients with chronic migraine: A CHOIR study.
    Headache. 2021;61:872-881.
    >> Share

    May 2021
  289. POPOFF E, Johnston K, Croop R, Thiry A, et al
    Matching-adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and health-related quality of life in the treatment of migraine.
    Headache. 2021 May 22. doi: 10.1111/head.14128.
    >> Share

  290. CHIANG CC, Halker Singh R, Lalvani N, Shubin Stein K, et al
    Patient experience of telemedicine for headache care during the COVID-19 pandemic: An American Migraine Foundation survey study.
    Headache. 2021 May 21. doi: 10.1111/head.14110.
    >> Share

  291. LIPTON RB, Dodick DW, Ailani J, McGill L, et al
    Patient-identified most bothersome symptom in preventive migraine treatment with eptinezumab: A novel patient-centered outcome.
    Headache. 2021 May 20. doi: 10.1111/head.14120.
    >> Share

  292. SAKAI F, Takeshima T, Homma G, Tanji Y, et al
    Phase 2 randomized placebo-controlled study of lasmiditan for the acute treatment of migraine in Japanese patients.
    Headache. 2021 May 15. doi: 10.1111/head.14122.
    >> Share

  293. ZIPLOW J
    The importance of studying comorbidities in migraine.
    Headache. 2021;61:697.
    >> Share

  294. GREENE KA
    The status of intravenous dihydroergotamine for pediatric headache: Status migrainosus and beyond.
    Headache. 2021;61:698-699.
    >> Share

    April 2021
  295. JAKATE A, Blumenfeld AM, Boinpally R, Butler M, et al
    Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene-related peptide-targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drug-drug interaction study.
    Headache. 2021 Apr 5. doi: 10.1111/head.14095.
    >> Share

  296. YIN JH, Lin YK, Yang CP, Liang CS, et al
    Prevalence and association of lifestyle and medical-, psychiatric-, and pain-related comorbidities in patients with migraine: A cross-sectional study.
    Headache. 2021 Apr 5. doi: 10.1111/head.14106.
    >> Share

  297. AURORA SK, Shrewsbury SB, Ray S, Hindiyeh N, et al
    A link between gastrointestinal disorders and migraine: Insights into the gut-brain connection.
    Headache. 2021 Apr 1. doi: 10.1111/head.14099.
    >> Share

  298. BUSE DC, Armand CE, Charleston L 4th, Reed ML, et al
    Barriers to care in episodic and chronic migraine: Results from the Chronic Migraine Epidemiology and Outcomes Study.
    Headache. 2021 Apr 1. doi: 10.1111/head.14103.
    >> Share

  299. HODGSON SE, Harding AM, Bourke EM, Taylor DM, et al
    A prospective, randomized, double-blind trial of intravenous chlorpromazine versus intravenous prochlorperazine for the treatment of acute migraine in adults presenting to the emergency department.
    Headache. 2021 Apr 1. doi: 10.1111/head.14091.
    >> Share

  300. LIPTON RB, Cohen JM, Galic M, Seminerio MJ, et al
    Effects of fremanezumab in patients with chronic migraine and comorbid depression: Subgroup analysis of the randomized HALO CM study.
    Headache. 2021;61:662-672.
    >> Share

  301. MARMURA MJ
    Comparing treatments in the emergency department: What works for migraine?
    Headache. 2021;61:567-568.
    >> Share

  302. HINES DM, Shah S, Multani JK, Wade RL, et al
    Erenumab patient characteristics, medication adherence, and treatment patterns in the United States.
    Headache. 2021;61:590-602.
    >> Share

    March 2021
  303. NAEGEL S, Burow P, Holle D, Stoevesandt D, et al
    Erenumab for migraine prevention in a patient with mitochondrial encephalopathy, lactate acidosis, and stroke-like episodes syndrome: A case report.
    Headache. 2021 Mar 29. doi: 10.1111/head.14101.
    >> Share

  304. TRIVEDI M, Dumkrieger G, Chong CD, Dodick DW, et al
    Impact of abuse on migraine-related sensory hypersensitivity symptoms: Results from the American Registry for Migraine Research.
    Headache. 2021 Mar 29. doi: 10.1111/head.14100.
    >> Share

  305. SAKAI F, Takeshima T, Tatsuoka Y, Hirata K, et al
    Long-term efficacy and safety during open-label erenumab treatment in Japanese patients with episodic migraine.
    Headache. 2021 Mar 25. doi: 10.1111/head.14096.
    >> Share

  306. LIU Y, Xu F, Wheaton AG, Greenlund KJ, et al
    The association between inflammatory bowel disease and migraine or severe headache among US adults: Findings from the National Health Interview Survey, 2015-2016.
    Headache. 2021 Mar 23. doi: 10.1111/head.14087.
    >> Share

  307. VGONTZAS A, Li W, Mostofsky E, Mittleman MA, et al
    Baseline sleep quality, stress, and depressive symptoms, and subsequent headache occurrence in a six-week prospective cohort study of patients with episodic migraine.
    Headache. 2021 Mar 22. doi: 10.1111/head.14105.
    >> Share

  308. WITTEN A, Marotta D, Cohen-Gadol A
    Developmental innervation of cranial dura mater and migraine headache: A narrative literature review.
    Headache. 2021 Mar 22. doi: 10.1111/head.14102.
    >> Share

  309. COWAN RP, Gross NB, Sweeney MD, Sagare AP, et al
    Evidence that blood-CSF barrier transport, but not inflammatory biomarkers, change in migraine, while CSF sVCAM1 associates with migraine frequency and CSF fibrinogen.
    Headache. 2021 Mar 16. doi: 10.1111/head.14088.
    >> Share

  310. BLUMENFELD AM, Goadsby PJ, Dodick DW, Hutchinson S, et al
    Efficacy of ubrogepant based on prior exposure and response to triptans: A post hoc analysis.
    Headache. 2021;61:422-429.
    >> Share

    February 2021
  311. ASHINA H, Moskowitz MA
    Shared biological foundations of post-traumatic headache and migraine.
    Headache. 2021 Feb 25. doi: 10.1111/head.14084.
    >> Share

  312. MCGINLEY JS, Wirth RJ, Pavlovic JM, Donoghue S, et al
    Between and within-woman differences in the association between menstruation and migraine days.
    Headache. 2021 Feb 19. doi: 10.1111/head.14058.
    >> Share

  313. MCGINLEY JS, Houts CR, Nishida TK, Buse DC, et al
    Systematic review of outcomes and endpoints in preventive migraine clinical trials.
    Headache. 2021 Feb 18. doi: 10.1111/head.14069.
    >> Share

  314. SHAO Q, Rascati KL, Lawson KA, Wilson JP, et al
    Impact of emergency department opioid use on future health resource utilization among patients with migraine.
    Headache. 2021 Feb 18. doi: 10.1111/head.14071.
    >> Share

  315. KAWATA AK, Shah N, Poon JL, Shaffer S, et al
    Understanding the migraine treatment landscape prior to the introduction of calcitonin gene-related peptide inhibitors: Results from the Assessment of TolerabiliTy and Effectiveness in MigrAINe Patients using Preventive Treatment (ATTAIN) study.
    Headache. 2021 Feb 16. doi: 10.1111/head.14053.
    >> Share

  316. GELFAND AA, Ross AC, Pavitt S, Szperka CL, et al
    Would chronotype change the impact of the relationship between early school schedules and adolescent migraine frequency? A response.
    Headache. 2021 Feb 5. doi: 10.1111/head.14061.
    >> Share

  317. GELFAND AA, Poland G
    Migraine treatment and COVID-19 vaccines: no cause for concern.
    Headache. 2021 Feb 5. doi: 10.1111/head.14086.
    >> Share

  318. VANDERPLUYM JH
    Once too many: Impact of emergency department opioid use on future health resource utilization among patients with migraine.
    Headache. 2021;61:229-230.
    >> Share

  319. BURCH R
    Outcomes in clinical trials for migraine: What should we measure and who should decide?
    Headache. 2021;61:227-228.
    >> Share

  320. HOUTS CR, McGinley JS, Nishida TK, Buse DC, et al
    Systematic review of outcomes and endpoints in acute migraine clinical trials.
    Headache. 2021;61:263-275.
    >> Share

  321. PINTO MJ, Guerrero AL, Costa A
    Botulinum toxin as a novel therapeutic approach for auriculotemporal neuralgia.
    Headache. 2021;61:392-395.
    >> Share

    January 2021
  322. SLAVIN M, Li H, Khatri M, Frankenfeld C, et al
    Dietary magnesium and migraine in adults: A cross-sectional analysis of the National Health and Nutrition Examination Survey 2001-2004.
    Headache. 2021 Jan 27. doi: 10.1111/head.14065.
    >> Share

  323. SPECK RM, Yu R, Ford JH, Ayer DW, et al
    Psychometric validation and meaningful within-patient change of the Migraine-Specific Quality of Life questionnaire version 2.1 electronic patient-reported outcome in patients with episodic and chronic migraine.
    Headache. 2021 Jan 22. doi: 10.1111/head.14031.
    >> Share

  324. NEIVA GR, Meira E Cruz M, Salles C
    Would chronotype change the impact of the relationship between early school schedules and adolescent migraine frequency?
    Headache. 2021 Jan 20. doi: 10.1111/head.14060.
    >> Share

  325. SCHWEDT TJ, Hentz JG, Sahai-Srivastava S, Spare NM, et al
    Headache characteristics and burden from chronic migraine with medication overuse headache: Cross-sectional observations from the Medication Overuse Treatment Strategy trial.
    Headache. 2021 Jan 12. doi: 10.1111/head.14056.
    >> Share

  326. PAVLOVIC JM, Yu JS, Silberstein SD, Reed ML, et al
    Evaluation of the 6-item Identify Chronic Migraine screener in a large medical group.
    Headache. 2021 Jan 9. doi: 10.1111/head.14035.
    >> Share

  327. LIAMPAS I, Mylonas KS, Brotis A, Dervenis P, et al
    Serum lipid abnormalities in migraine: A meta-analysis of observational studies.
    Headache. 2021 Jan 4. doi: 10.1111/head.14039.
    >> Share

  328. O'BRIEN HL, Halker Singh RB
    Breaking down barriers to care: Understanding migraine knowledge gaps among women's healthcare providers.
    Headache. 2021;61:7-8.
    >> Share

  329. KARVOUNIDES D, Marzouk M, Ross AC, VanderPluym JH, et al
    The intersection of COVID-19, school, and headaches: Problems and solutions.
    Headache. 2021;61:190-201.
    >> Share

  330. BERTELS Z, Witkowski WD, Asif S, Siegersma K, et al
    A non-convulsant delta-opioid receptor agonist, KNT-127, reduces cortical spreading depression and nitroglycerin-induced allodynia.
    Headache. 2021;61:170-178.
    >> Share

    December 2020
  331. OSWALD JC, Schuster NM
    A randomized, double-dummy, emergency department-based study of greater occipital nerve block with bupivacaine versus intravenous metoclopramide for treatment of migraine: A comment.
    Headache. 2020 Dec 31. doi: 10.1111/head.14044.
    >> Share

  332. SPECTOR AR, Kerkow JF, Collins TA
    Sleep terrors prodromal for migraine headaches responsive to galcanezumab: A case report.
    Headache. 2020 Dec 31. doi: 10.1111/head.14055.
    >> Share

  333. CONNELLY MA, Boorigie ME
    Feasibility of using "SMARTER" methodology for monitoring precipitating conditions of pediatric migraine episodes.
    Headache. 2020 Dec 31. doi: 10.1111/head.14028.
    >> Share

  334. CHENG V, Billups SJ, Saseen JJ
    Prescribing practices of migraine-specific pharmacotherapy associated with emergency department use for migraine.
    Headache. 2020 Dec 30. doi: 10.1111/head.14029.
    >> Share

  335. VERHAAK AMS, Williamson A, Johnson A, Murphy A, et al
    Migraine diagnosis and treatment: A knowledge and needs assessment of women's healthcare providers.
    Headache. 2020 Dec 30. doi: 10.1111/head.14027.
    >> Share

  336. PRESSMAN AR, Buse DC, Jacobson AS, Vaidya SJ, et al
    The migraine signature study: Methods and baseline results.
    Headache. 2020 Dec 23. doi: 10.1111/head.14033.
    >> Share

  337. BURCH R, Rizzoli P, Loder E
    The prevalence and impact of migraine and severe headache in the United States: Updated age, sex, and socioeconomic-specific estimates from government health surveys.
    Headache. 2020 Dec 21. doi: 10.1111/head.14024.
    >> Share

  338. HAGAN KK, Li W, Mostofsky E, Bertisch SM, et al
    Prospective cohort study of routine exercise and headache outcomes among adults with episodic migraine.
    Headache. 2020 Dec 21. doi: 10.1111/head.14037.
    >> Share

  339. HERSHEY AD, Lin T, Gruper Y, Harris D, et al
    Remote electrical neuromodulation for acute treatment of migraine in adolescents.
    Headache. 2020 Dec 21. doi: 10.1111/head.14042.
    >> Share

  340. BARBANTI P, Aurilia C, Egeo G, Fofi L, et al
    Erenumab in the prevention of high-frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life study.
    Headache. 2020 Dec 18. doi: 10.1111/head.14032.
    >> Share

  341. TORABI SJ, Kasle DA, Savoca EL, Gottschalk CH, et al
    Characterizing the providers of and reimbursement for chronic migraine chemodenervation among the Medicare population.
    Headache. 2020 Dec 18. doi: 10.1111/head.14040.
    >> Share

  342. LIPTON RB, Buse DC, Dodick DW, Schwedt TJ, et al
    Burden of increasing opioid use in the treatment of migraine: Results from the Migraine in America Symptoms and Treatment Study.
    Headache. 2020 Dec 16. doi: 10.1111/head.14018.
    >> Share

  343. SMITH M, Nakamoto M, Crocker J, Tiffany Morden F, et al
    Early impact of the COVID-19 pandemic on outpatient migraine care in Hawaii: Results of a quality improvement survey.
    Headache. 2020 Dec 14. doi: 10.1111/head.14030.
    >> Share

  344. DIENER HC, Marmura MJ, Tepper SJ, Cowan R, et al
    Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache: Subgroup analysis of PROMISE-2.
    Headache. 2020 Dec 13. doi: 10.1111/head.14036.
    >> Share

    November 2020
  345. GELFAND AA, Pavitt S, Ross AC, Szperka CL, et al
    Later high school start time is associated with lower migraine frequency in adolescents.
    Headache. 2020 Nov 25. doi: 10.1111/head.14016.
    >> Share

  346. NAHMAN-AVERBUCH H, Thomas PL, Schneider VJ 2nd, Chamberlin LA, et al
    Spatial aspects of pain modulation are not disrupted in adolescents with migraine.
    Headache. 2020 Nov 24. doi: 10.1111/head.14017.
    >> Share

  347. TIRITICCO M, Vanotti A, Mantica D, Coppola A, et al
    Migraine With Exclusive Olfactory Aura: Case Report and Literature Review.
    Headache. 2020 Nov 18. doi: 10.1111/head.14014.
    >> Share

  348. MINEN MT, Adhikari S, Padikkala J, Tasneem S, et al
    Smartphone-Delivered Progressive Muscle Relaxation for the Treatment of Migraine in Primary Care: A Randomized Controlled Trial.
    Headache. 2020 Nov 16. doi: 10.1111/head.14010.
    >> Share

  349. LIPTON RB, Cohen JM, Bibeau K, Galic M, et al
    Reversion From Chronic Migraine to Episodic Migraine in Patients Treated With Fremanezumab: Post Hoc Analysis From HALO CM Study.
    Headache. 2020 Nov 11. doi: 10.1111/head.13997.
    >> Share

  350. POLK AN, Protti TA, Smitherman TA
    Allodynia and Disability in Migraine: The Mediating Role of Stress.
    Headache. 2020 Nov 9. doi: 10.1111/head.14012.
    >> Share

  351. DODICK DW, Gottschalk C, Cady R, Hirman J, et al
    Eptinezumab Demonstrated Efficacy in Sustained Prevention of Episodic and Chronic Migraine Beginning on Day 1 After Dosing.
    Headache. 2020 Nov 9. doi: 10.1111/head.14007.
    >> Share

  352. PILATI L, Battaglia G, Di Stefano V, Di Marco S, et al
    Migraine and Sport in a Physically Active Population of Students: Results of a Cross-Sectional Study.
    Headache. 2020 Nov 7. doi: 10.1111/head.14015.
    >> Share

  353. GILL K, Chia VM, Hernandez RK, Navetta M, et al
    Rates of Vascular Events in Patients With Migraine: A MarketScan((R)) Database Retrospective Cohort Study.
    Headache. 2020 Nov 3. doi: 10.1111/head.14001.
    >> Share

  354. BUSE DC, McGinley JS, Lipton RB
    Predicting the Future of Migraine Attack Prediction.
    Headache. 2020;60:2125-2128.
    >> Share

  355. VGONTZAS A, Li W, Mostofsky E, Mittleman MA, et al
    The Sleep - Migraine Enigma: A Comment.
    Headache. 2020;60:2610.
    >> Share

  356. FORD JH, Kurth T, Starling AJ, Ayer DW, et al
    Migraine Headache Day Response Rates and the Implications to Patient Functioning: An Evaluation of 3 Randomized Phase 3 Clinical Trials of Galcanezumab in Patients With Migraine.
    Headache. 2020;60:2304-2319.
    >> Share

    October 2020
  357. ANDERSON CC, Ray CA, Butler MR, Darken RS, et al
    Effects of Procedural Discomfort and Expectation of Benefit on Therapy Continuation in Chronic Migraine Patients Treated With OnabotulinumtoxinA.
    Headache. 2020 Oct 31. doi: 10.1111/head.14008.
    >> Share

  358. BOLAY H, Ozge A, Uluduz D, Baykan B, et al
    Are Migraine Patients at Increased Risk for Symptomatic Coronavirus Disease 2019 Due to Shared Comorbidities?
    Headache. 2020 Oct 30. doi: 10.1111/head.13998.
    >> Share

  359. KRYMCHANTOWSKI A, Jevoux C, Silva-Neto RP, Krymchantowski AG, et al
    Migraine Treatment in Emergency Departments of Brazil: A Retrospective Study of 2 Regions.
    Headache. 2020 Oct 27. doi: 10.1111/head.13999.
    >> Share

  360. BLUMENFELD AM, Silberstein SD
    Response to "Modifications to the PREEMPT Protocol for OnabotulinumtoxinA Injections for Chronic Migraine in Clinical Practice".
    Headache. 2020 Oct 27. doi: 10.1111/head.13996.
    >> Share

  361. SMITHERMAN TA, Tietjen GE, Schuh K, Skljarevski V, et al
    Efficacy of Galcanezumab for Migraine Prevention in Patients With a Medical History of Anxiety and/or Depression: A Post Hoc Analysis of the Phase 3, Randomized, Double-Blind, Placebo-Controlled REGAIN, and Pooled EVOLVE-1 and EVOLVE-2 Studies.
    Headache. 2020 Oct 16. doi: 10.1111/head.13970.
    >> Share

  362. BUSE DC, Reed ML, Fanning KM, Bostic RC, et al
    Demographics, Headache Features, and Comorbidity Profiles in Relation to Headache Frequency in People With Migraine: Results of the American Migraine Prevalence and Prevention (AMPP) Study.
    Headache. 2020 Oct 14. doi: 10.1111/head.13966.
    >> Share

  363. TU S, Liew D, Ademi Z, Owen AJ, et al
    The Health and Productivity Burden of Migraines in Australia.
    Headache. 2020 Oct 7. doi: 10.1111/head.13969.
    >> Share

  364. HOLSTEEN KK, Hittle M, Barad M, Nelson LM, et al
    Development and Internal Validation of a Multivariable Prediction Model for Individual Episodic Migraine Attacks Based on Daily Trigger Exposures.
    Headache. 2020 Oct 6. doi: 10.1111/head.13960.
    >> Share

  365. BEUTHIN J, Veronesi M, Grosberg B, Evans RW, et al
    Gluten-Free Diet and Migraine.
    Headache. 2020 Oct 6. doi: 10.1111/head.13993.
    >> Share

  366. GHANSHANI S, Chen C, Lin B, Duan L, et al
    Risk of Acute Myocardial Infarction, Heart Failure, and Death in Migraine Patients Treated with Triptans.
    Headache. 2020 Oct 5. doi: 10.1111/head.13959.
    >> Share

  367. TOMKINS E, Craven A, Ruttledge M
    Migraine and Headache Care in the Republic of Ireland: History and a Vision for the Future Influenced by the COVID-19 Pandemic.
    Headache. 2020 Oct 3. doi: 10.1111/head.13985.
    >> Share

    September 2020
  368. SWART ECS, Good CB, Henderson R, Manolis C, et al
    Identifying Outcome Measures for Migraine Value-Based Contracting Using the Delphi Method.
    Headache. 2020 Sep 30. doi: 10.1111/head.13978.
    >> Share

  369. CHENG S, Jenkins B, Limberg N, Hutton E, et al
    Erenumab in Chronic Migraine: An Australian Experience.
    Headache. 2020 Sep 29. doi: 10.1111/head.13968.
    >> Share

  370. HAMILTON KT, Halker Singh RB, Ailani J, Butterfield RJ, et al
    Migraine Treatment in Pregnancy: An American Headache Society Survey.
    Headache. 2020 Sep 29. doi: 10.1111/head.13974.
    >> Share

  371. FRIEDMAN BW, Irizarry E, Williams A, Solorzano C, et al
    A Randomized, Double-Dummy, Emergency Department-Based Study of Greater Occipital Nerve Block With Bupivacaine vs Intravenous Metoclopramide for Treatment of Migraine.
    Headache. 2020 Sep 27. doi: 10.1111/head.13961.
    >> Share

  372. QUINTAS M, Neto JL, Sequeiros J, Sousa A, et al
    Going Deep into Synaptic Vesicle Machinery Genes and Migraine Susceptibility - A Case-Control Association Study.
    Headache. 2020 Sep 26. doi: 10.1111/head.13957.
    >> Share

  373. TOPTAN T, Aktan C, Basari A, Bolay H, et al
    Case Series of Headache Characteristics in COVID-19: Headache Can Be an Isolated Symptom.
    Headache. 2020;60:1788-1792.
    >> Share

  374. SAMPAIO ROCHA-FILHO PA, Voss L
    Persistent Headache and Persistent Anosmia Associated With COVID-19.
    Headache. 2020;60:1797-1799.
    >> Share

  375. PORTA-ETESSAM J, Matias-Guiu JA, Gonzalez-Garcia N, Gomez Iglesias P, et al
    Spectrum of Headaches Associated With SARS-CoV-2 Infection: Study of Healthcare Professionals.
    Headache. 2020;60:1697-1704.
    >> Share

  376. BOBKER SM, Robbins MS
    COVID-19 and Headache: A Primer for Trainees.
    Headache. 2020;60:1806-1811.
    >> Share

  377. LIPTON RB, Seng EK, Chu MK, Reed ML, et al
    The Effect of Psychiatric Comorbidities on Headache-Related Disability in Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study.
    Headache. 2020;60:1683-1696.
    >> Share

    July 2020
  378. MINEN MT, Jaran J, Boyers T, Corner S, et al
    Understanding What People With Migraine Consider to be Important Features of Migraine Tracking: An Analysis of the Utilization of Smartphone-Based Migraine Tracking With a Free-Text Feature.
    Headache. 2020;60:1402-1414.
    >> Share

  379. SUZUKI K, Fujita H, Hirata K
    Parkinson's Disease and Headache: Is there a Relevant Relationship?
    Headache. 2020;60:1440-1441.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016